Develops drugs for cardiometabolic diseases.
Jun 2026Revenue $7.12M/yrExpenses $252M/yr
No trendCash runway ≈ 4.4 years from Jun 2026
Figures by year
When will NewAmsterdam Pharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $7.12M and expenses $252M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $22.5M | $248M | −$226M |
| Dec 2024 | $45.6M | $222M | −$176M |
| Dec 2023 | $14.1M | $197M | −$183M |
| Dec 2022 | $103M | $106M | −$3.56M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.